NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
1.
ORGANIZATION AND DESCRIPTION OF BUSINESS
Aixin
Life International, Inc. (the “Company” or “Aixin Life” or “we”)
was incorporated under the laws of the State of Colorado on December 30, 1987 under the name Mercari Communications Group, Ltd (“Mercari”).
Mercari’s business failed in 1990. Mercari conducted no operating activities from June 1, 1990 to August 31, 2001 and was dormant.
During
each year since Mercari was reactivated until 2017, the Company had no revenue and had losses approximately equal to the expenditures
required to reactivate and comply with filing and reporting obligations. Expenditures were paid by Mercari from capital contributions
and loans made by Mercari’s principal stockholders and entities controlled by Mercari’s directors.
On
January 20, 2017, Algodon sold 10,955,500 shares of the Company’s common stock, 96.5% of the Company’s outstanding shares,
to China Concentric, for $260,000, and assigned its right to the repayment of $150,087 of non-interest bearing advances to the Company
for working capital, pursuant to a Stock Purchase Agreement dated December 20, 2016, as amended. Prior to entering into the Stock Purchase
Agreement with Algodon, neither China Concentric nor any of its affiliates had any relationship to the Company, Algodon or any of their
respective affiliates.
On
February 2, 2017, Mr. Quanzhong Lin purchased 7,380,352 shares of the Company’s common stock, 65.0% of its outstanding shares from
China Concentric for $300,000, pursuant to a Stock Purchase Agreement dated December 21, 2016, which resulted in a change in control
of our company.
On
December 12, 2017, the Company issued 56,838,151 shares of common stock to Mr. Lin, the sole stockholder of AiXin (BVI) International
Group Co., Ltd. a British Virgin Islands corporation (“AiXin BVI”), for his shares of AiXin BVI, pursuant to a Share Exchange
Agreement.
As
a result of the Share Exchange, AiXin BVI became the Company’s wholly-owned subsidiary, and the Company now owns all of the outstanding
shares of HK AiXin International Group Co., Limited, a Hong Kong limited company (“AiXin HK”), which in turn owns all of
the outstanding shares of Chengdu AiXinZhonghong Biological Technology Co., Ltd., a Chinese limited company (“AiXinZhonghong”),
which markets and sells premium-quality nutritional products in China.
AiXin
BVI was incorporated on September 21, 2017 as a holding company and AiXin HK was established in Hong Kong on February 25, 2016 as an
intermediate holding company. AiXinZhonghong was established in the People’s Republic of China (“PRC”) on March 4,
2013, and on May 27, 2017, the local government of the PRC issued a certificate of approval regarding the foreign ownership of AiXinZhonghong
by AiXin HK. Neither AiXin BVI nor AiXin HK had operations prior to December 12, 2017.
For
accounting purposes, the acquisition was accounted for as a reverse acquisition and treated as a recapitalization of the Company effected
by a share exchange, with AiXin BVI as the accounting acquirer. Since neither AiXin BVI nor AiXin HK had operations prior to December
12, 2017, the historical consolidated financial statements of AiXinZhonghong are now the historical consolidated financial statements
of the Company. The assets and liabilities of AiXinZhonghong were brought forward at their book value and no goodwill was recognized.
Effective
February 1, 2018, pursuant to Articles of Amendment to the Company’s Articles of Incorporation filed with the Secretary of State
of Colorado, the Company changed its name to AiXin Life International., Inc (“Aixin Life”).
The
Company, through its indirectly owned AiXinZhonghong subsidiary, mainly develops and distributes consumer products by offering a line
of nutritional products. The Company sells the products through exhibition events, conferences, and person-to-person marketing. Beginning
in 2019, the Company began to provide advertising services to clients which engaged the Company to help distribute their products. The
Company’s business mainly focuses on a proactive approach to its customers such as hosting events for clients, which it believes
is ideally suited to marketing its products because sales of nutrition products are strengthened by ongoing personal contact and support,
coaching and education of its clients, as to the benefits of a healthy and active lifestyle.
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis
of Presentation
The
accompanying consolidated financial statements are
prepared in conformity with U.S. Generally Accepted Accounting Principles (“US GAAP”). The functional currency of AiXinZhonghong
is Chinese Renminbi (‘‘RMB’’). The accompanying consolidated financial
statements are translated from RMB and presented in U.S. dollars (“USD”).
The
consolidated financial statements include the accounts of the Company and its current wholly owned subsidiaries, AiXin HK and AiXinZhonghong.
Intercompany transactions and accounts were eliminated in consolidation.
Unaudited
Interim Financial Information
These
unaudited interim financial statements have been prepared in accordance with GAAP for interim financial reporting and the rules and regulations
of the Securities and Exchange Commission that permit reduced disclosure for interim periods. Therefore, certain information and footnote
disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted. In the opinion
of management, all adjustments of a normal recurring nature necessary for a fair presentation of the financial position, results of operations
and cash flows for the periods presented have been made. The results of operations for the interim periods presented are not necessarily
indicative of the results to be expected for the year ending December 31, 2021.
The
balance sheets and certain comparative information as of December 31, 2020 are derived from the audited financial statements and related
notes for the year ended December 31, 2020, included in the Company’s 2020 Annual Report on Form 10-K. These unaudited interim
financial statements should be read in conjunction with the annual consolidated financial statements and the accompanying notes contained
in our Annual Report on Form 10-K for the year ended December 31, 2020.
Reclassification
Certain
prior period amounts have been reclassified to conform to the current period presentation and had no effect on previously reported consolidated
net income (loss) or accumulated deficit.
Covid
– 19
On
March 11, 2020, the World Health Organization announced that infections caused by the corona virus disease of 2019 (“COVID-19”)
had become pandemic. The Government of China has adopted various regulations and orders, including mandatory quarantines, limits on the
number of people that may gather in one location, closing non-essential businesses and travel bans to limit the spread of the disease.
Many of these measures have been relaxed due to the decrease in the prevalence of Covid-19 in China. To date, the ongoing operations
of the Company have not been materially adversely effected by the measures taken to limit the spread of the disease in China.
Financial
impacts related to COVID-19, including the Company’s actions and costs incurred in response to the pandemic, were not material
to the Company’s financial position, results of operations or cash flows for the period ended June 30, 2021. The Company has implemented
procedures to promote employee and customer safety. These measures will not significantly increase its operating costs. However, the
Company cannot predict with certainty what measures may be taken by its suppliers and customers and the impact these measures may have
on its 2021 financial position, results of operations or cash flows.
Use
of Estimates
In
preparing consolidated financial statements in
conformity with US GAAP, management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures
of contingent assets and liabilities at the dates of the consolidated financial statements,
as well as the reported amounts of revenues and expenses during the reporting period.
Significant
estimates, required by management, include the recoverability of long-lived assets, allowance for doubtful accounts, and the reserve
for obsolete and slow-moving inventories. Actual results could differ from those estimates.
Cash
and Cash Equivalents
For
financial statement purposes, the Company considers all highly liquid investments with an original maturity of three months or less to
be cash and cash equivalents.
Accounts
Receivable
The
Company’s policy is to maintain an allowance for potential credit losses on accounts receivable. Management reviews the composition
of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends
and changes in customer payment patterns to evaluate the adequacy of these reserves. As of June 30, 2021, and December 31, 2020, the
bad debt allowance was $150,093 and $148,520, respectively.
Inventory
Inventory
mainly consists of health supplements. Inventory is valued at the lower of average cost or market, cost being determined on a moving
weighted average method at the end of the month. Management compares the cost of inventories with the net realizable value and an allowance
is made for writing down inventories to market value, if lower. The Company recorded no inventory impairment for the three and six months
ended June 30, 2021 and 2020.
In
July 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-11, “Inventory (Topic 330) - Simplifying the Measurement
of Inventory,” which requires that inventory within the scope of the guidance be measured at the lower of cost and net realizable
value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of
completion, disposal, and transportation.
Property
and Equipment
Property
and equipment are stated at cost, less accumulated depreciation, and impairment losses, if any. Major repairs and betterments that significantly
extend original useful lives or improve productivity are capitalized and depreciated over the period benefited. Maintenance and repairs
are expensed as incurred. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation
are removed from the respective accounts, and any gain or loss is included in operations. Depreciation
of property and equipment is provided using the straight-line method for substantially all assets with 5% salvage value and estimated
lives as follows:
SCHEDULE OF ESTIMATED USEFUL LIVES OF PROPERTY AND EQUIPMENT
Office furniture
|
|
5 years
|
|
Electronic Equipment
|
|
3 years
|
|
Vehicles
|
|
5 years
|
|
Impairment
of Long-Lived Assets
Long-lived
assets, which include property and equipment and intangible assets, are reviewed for impairment whenever events or changes in circumstances
indicate that the carrying amount of an asset may not be recoverable, but at least annually.
Recoverability
of long-lived assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future
cash flows expected to be generated by it. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an
impairment charge is recognized by the amount by which the carrying amount of the asset exceeds its fair value. Fair value is generally
determined using the asset’s expected future discounted cash flows or market value, if readily determinable. Based on its review,
the Company believes that, as of June 30, 2021 and December 31, 2020, there were no significant impairments of its long-lived assets.
Income
Taxes
Income
taxes are accounted for using an asset and liability method. Under this method, deferred income taxes are recognized for the tax consequences
in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end
based on enacted tax laws and statutory tax rates, applicable to the periods in which the differences are expected to affect taxable
income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
The
Company follows Accounting Standards Codification (“ASC”) Topic 740, which prescribes a more-likely-than-not threshold for
financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. ASC Topic 740 also provides
guidance on recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities,
accounting for interest and penalties associated with tax positions, accounting for income taxes in interim periods, and income tax disclosures.
Under
ASC Topic 740, when tax returns are filed, it is likely that some positions taken would be sustained upon examination by the taxing authorities,
while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately
sustained. The benefit of a tax position is recognized in the consolidated financial statements in the period during which, based on
all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including
the resolution of appeals or litigation processes, if any. Tax positions taken are not offset or aggregated with other positions. Tax
positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than
50% likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions
taken that exceeds the amount measured as described above is reflected as a liability for unrecognized tax benefits in the accompanying
balance sheets along with any associated interest and penalties that would be payable to the taxing authorities upon examination. Interest
associated with unrecognized tax benefits is classified as interest expense and penalties are classified in selling, general and administrative
expenses in the statement of income.
At
June 30, 2021 and December 31, 2020, the Company did not take any uncertain positions that would necessitate recording a tax related
liability.
Revenue
Recognition
ASU
No. 2014-09, Revenue from Contracts with Customers (“Topic 606”), became effective for the Company on January
1, 2018. The Company’s revenue recognition disclosure reflects its updated accounting policies that are affected by this new standard.
The Company applied the “modified retrospective” transition method for open contracts for the implementation of Topic
606. As revenues are and have been primarily from the delivery of health supplements and the performance of related advertising services,
and the Company has no significant post-delivery obligations, this did not result in a material recognition of revenue on the Company’s
accompanying consolidated financial statements for the cumulative impact of applying this new standard. The Company made no adjustments
to its previously-reported total revenues, as those periods continue to be presented in accordance with its historical accounting practices
under Topic 605, Revenue Recognition.
Revenue
from sale of goods under Topic 606 is recognized in a manner that reasonably reflects the delivery of the Company’s products
and services to customers in return for expected consideration and includes the following elements:
|
●
|
executed contract(s) with customers that the Company
believes is legally enforceable;
|
|
●
|
identification of performance obligation in the respective
contract;
|
|
●
|
determination of the transaction price for each performance
obligation in the respective contract;
|
|
●
|
allocation of the transaction price to each performance
obligation; and
|
|
●
|
recognition of revenue only when the Company satisfies
each performance obligation.
|
The
Company’s revenue from sale of goods is recognized when goods are shipped to the customer and no other obligation exits. The Company
does not provide unconditional return or other concessions to the customer. The Company’s sales policy allows for the return of
unopened products for cash after deducting certain service and transaction fees. As an alternative to the product return option, the
customers have options of asking for an exchange for products with the same value.
Sales
revenue represents the invoiced value of goods, net of value-added taxes (“VAT”). All of the Company’s products sold
in China are subject to the PRC VAT of 17% of the gross sales price prior to May 1, 2018, 16% since May 1, 2018 and 13% since April 1,
2019. This VAT may be offset by VAT paid by the Company on raw materials and other materials purchased in China. The Company records
VAT payable and VAT receivable net of payments in the financial statements. The VAT tax return is filed offsetting the payables against
the receivables. Sales and purchases are recorded net of VAT collected and paid as the Company acts as an agent for the government.
Advertising
Revenue
Commencing
in the third quarter of 2019, the Company began to provide advertising services to its clients. Advertising contracts are signed to establish
the price and advertising services to be provided. Pursuant to the advertising contracts, the Company provides advertising and marketing
services to its clients through exhibition events, conferences, and person-to-person marketing. The Company performs a credit assessment
of the customer to assess the collectability of the contract price prior to entering into contracts.
Most
of the advertisement contracts designated that the Company perform such advertising services for its clients through exhibition events,
conferences, and person-to-person marketing during the contracted period, regardless of the number of such events. As such, the Company
determined that the performance obligation is satisfied over time during the contracted period and revenue is recognized accordingly.
Such advertising revenue amounted to $802,817 and $379,899 for the three months ended June 30, 2021 and 2020, respectively. Such advertising
revenue amounted to $1,297,681 and $923,389 for the six months ended June 30, 2021 and 2020, respectively.
A
smaller proportion of the Company’s advertising revenue is generated from services to its clients through exhibition events, conferences,
and person-to-person marketing, and charges based on the number of promotional products sold. Such advertising revenue amounted to $0
for the three months ended June 30, 2021 and 2020. Such advertising revenue amounted to $0 and $6,439 for the six months ended June 30,
2021 and 2020, respectively.
Cost
of Goods Sold
Cost
of goods sold consists primarily of the cost of inventory purchases. Reserve for inventory allowance due to lower of cost or market is
also recorded in cost of goods sold.
Concentration
of Credit Risk
The
operations of the Company are in the PRC. Accordingly, the Company’s business, financial condition, and results of operations may
be influenced by the political, economic, and legal environments in the PRC, and by the general state of the PRC economy.
The
Company has cash on hand and demand deposits in accounts maintained with state-owned banks within the PRC. Cash in state-owned banks
is covered by insurance up to RMB 500,000 ($72,500) per bank. The Company has not experienced any losses in such accounts and believes
they are not exposed to any risks on its cash in these bank accounts.
During
the three months ended June 30, 2021, the Company had two major customers that accounted for over 10% of its total revenue.
SCHEDULE OF CONCENTRATION OF CREDIT RISK
Customer
|
|
Net sales for the three months
ended June 30, 2021
|
|
|
% of total revenue
|
|
A*
|
|
$
|
511,204
|
|
|
|
60
|
%
|
B
|
|
|
291,613
|
|
|
|
34
|
%
|
During
the six months ended June 30, 2021, the Company had two major customers that accounted for over 10% of its total revenue.
Customer
|
|
Net sales for the six months
ended June 30, 2021
|
|
|
% of total revenue
|
|
A*
|
|
$
|
1,006,068
|
|
|
|
65
|
%
|
B
|
|
|
291,613
|
|
|
|
19
|
%
|
During
the three months ended June 30, 2020, the Company had one major customer that accounted for over 10% of its total revenue.
Customer
|
|
Net sales for the three months
ended
June 30, 2020
|
|
|
% of total revenue
|
|
A*
|
|
$
|
379,899
|
|
|
|
88
|
%
|
During
the six months ended June 30, 2020, the Company had one major customer that accounted for over 10% of its total revenue.
Customer
|
|
Net sales for the six months
ended
June 30, 2020
|
|
|
% of total revenue
|
|
A*
|
|
$
|
923,389
|
|
|
|
88
|
%
|
During
the three months ended June 30, 2021, the Company had one major supplier that accounted for over 10% of its total purchases.
Supplier
|
|
Net purchases for the three
months ended
June 30, 2021
|
|
|
% of total purchase
|
|
A*
|
|
$
|
3,940
|
|
|
|
91
|
%
|
During
the six months ended June 30, 2021, the Company had one major supplier that accounted for over 10% of its total purchases.
Supplier
|
|
Net purchases for the six
months ended
June 30, 2021
|
|
|
% of total purchase
|
|
C
|
|
$
|
232,516
|
|
|
|
97
|
%
|
During
the three months ended June 30, 2020, the Company had two major suppliers that accounted for over 10% of its total purchases.
Supplier
|
|
Net purchase for the three months ended
June 30, 2020
|
|
|
% of total purchase
|
|
A*
|
|
$
|
41,528
|
|
|
|
67
|
%
|
D
|
|
|
19,636
|
|
|
|
32
|
%
|
During
the six months ended June 30, 2020, the Company had two major suppliers that accounted for over 10% of its total purchases.
Supplier
|
|
Net purchase for the six months ended
June 30, 2020
|
|
|
% of total purchase
|
|
A*
|
|
$
|
47,868
|
|
|
|
70
|
%
|
D
|
|
|
19,636
|
|
|
|
29
|
%
|
*
|
|
Represented
advertising revenues from this customer during the three and six months ended June 30, 2021
and 2020. The Company also purchased inventory from this customer in the three and six months
ended June 30, 2021 and 2020.
|
Leases
The
Company adopted FASB Accounting Standards Codification, Topic 842, Leases (“ASC 842”) using the modified retrospective approach,
electing the practical expedient that allows the Company not to restate prior to the adoption of the standard on January 1, 2019. As
such, the disclosures required under ASC 842 are not presented for periods before the date of adoption.
The
Company applied the following practical expedients in the transition to the new standard allowed under ASC 842:
Practical
Expedient
|
|
Description
|
Reassessment of expired
or existing contracts
|
|
The Company elected not to reassess, at the application
date, whether any expired or existing contracts contained leases, the lease classification for any expired or existing leases, and
the accounting for initial direct costs for any existing leases.
|
Use of hindsight
|
|
The Company elected to use hindsight in determining
the lease term (that is, when considering options to extend or terminate the lease and to purchase the underlying asset) and in assessing
impairment of right-to-use assets.
|
Reassessment of existing
or expired land easements
|
|
The Company elected not to evaluate existing or expired
land easements that were not previously accounted for as leases under ASC 840, as allowed under the transition practical expedient.
Going forward, new or modified land easements will be evaluated under ASU No. 2016-02.
|
Separation of lease and non-lease components
|
|
Lease agreements that contain both lease and non-lease
components are generally accounted for separately.
|
Short-term lease recognition exemption
|
|
The Company also elected the short-term lease recognition
exemption and will not recognize ROU assets or lease liabilities for leases with a term less than 12 months.
|
The
new leasing standard requires recognition of leases on the consolidated balance sheets as right-of-use (“ROU”) assets and
lease liabilities. ROU assets represent the Company’s right to use underlying assets for the lease terms and lease liabilities
represent the Company’s obligation to make lease payments arising from the leases. Operating lease ROU assets and operating lease
liabilities are recognized based on the present value and future minimum lease payments over the lease term at commencement date. The
Company’s future minimum based payments used to determine the Company’s lease liabilities mainly include minimum based rent
payments. As most of the Company’s leases do not provide an implicit rate, the Company uses its estimated incremental borrowing
rate based on the information available at commencement date in determining the present value of lease payments.
The
adoption of ASC 842 had no substantial impact on the Company’s consolidated balance sheets. The most significant impact was the
recognition of the operating lease right-of-use assets and the liability for operating leases. The adoption of ASC 842 did not result
in a cumulative-effect adjustment to the opening balance of retained earnings (accumulated deficit). In addition, the adoption of the
standard did not have a material impact on the Company’s results of operations or cash flows. Operating lease cost is recognized
as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses.
Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period
when the changes in facts and circumstances on which the variable lease payments are based occur.
Statement
of Cash Flows
In
accordance with ASC Topic 230, “Statement of Cash Flows,” cash flows from the Company’s operations are calculated
based on the local currencies using the average translation rates. As a result, amounts related to assets and liabilities reported on
the consolidated statements of cash flows will not necessarily agree with changes in the corresponding balances on the consolidated balance
sheets.
Fair
Value of Financial Instruments
The
carrying amounts of certain of the Company’s financial instruments, including cash and equivalents, accrued liabilities and accounts
payable, approximate their fair value due to their short maturities. FASB ASC Topic 825, “Financial Instruments,” requires
disclosure of the fair value of financial instruments held by the Company. The carrying amounts reported in the consolidated balance
sheets for current liabilities each qualify as financial instruments and are a reasonable estimate of their fair value because of the
short period of time between the origination of such instruments and their expected realization and the current market rate of interest.
Fair
Value Measurements and Disclosures
ASC
Topic 820, “Fair Value Measurements and Disclosures,” defines fair value, and establishes a three-level valuation hierarchy
for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The three levels are defined
as follow:
|
●
|
Level 1 inputs to the valuation methodology are quoted
prices (unadjusted) for identical assets or liabilities in active markets.
|
|
●
|
Level 2 inputs to the valuation methodology include
quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either
directly or indirectly, for substantially the full term of the financial instrument.
|
|
●
|
Level 3 inputs to the valuation methodology are unobservable
and significant to the fair value measurement.
|
As
of June 30, 2021 and December 31, 2020, the Company did not identify any assets and liabilities that are required to be presented on
the balance sheet at fair value.
Foreign
Currency Translation and Comprehensive Income (Loss)
The
functional currency of the Company is RMB. For financial reporting purposes, RMB is translated into USD as the reporting currency. Assets
and liabilities are translated at the exchange rate in effect at the balance sheet dates. Revenues and expenses are translated at the
average rate of exchange prevailing during the reporting period.
Translation
adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’
equity as “Accumulated other comprehensive income”. Gains and losses resulting from foreign currency transactions are included
in income. There was no significant fluctuation in the exchange rate for the conversion of RMB to USD after the balance sheet date.
The
Company uses FASB ASC Topic 220, “Comprehensive Income”. Comprehensive loss is comprised of net loss and all changes to the
statements of stockholders’ equity, except those due to investments by stockholders, changes in paid-in capital and distributions
to stockholders. Comprehensive income (loss) for the three and six months ended June 30, 2021 and 2020 consisted of net income (loss)
and foreign currency translation adjustments.
Earnings
per Share
Basic
income (loss) per share is computed on the basis of the weighted average number of common shares outstanding during the period.
Dilution
is computed by applying the treasury stock method for options and warrants. Under this method, options and warrants are assumed to be
exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase
common stock at the average market price during the period.
As
of June 30, 2021 and December 31, 2020, the Company did not have any potentially dilutive instruments.
Stock-Based
Compensation
The
Company periodically grants stock options, warrants and awards to employees and non-employees in non-capital raising transactions as
compensation for services rendered. The Company accounts for stock option, stock warrant and stock award grants to employees based on
the authoritative guidance provided by the FASB where the value of the award is measured on the date of grant and recognized over the
vesting period. The Company accounts for stock option, stock warrant and stock award grants to non-employees in accordance with the authoritative
guidance of the FASB where the value of the stock compensation is determined based upon the measurement date at either a) the date at
which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete.
Stock-based compensation charges generally are amortized over the vesting period on a straight-line basis. In certain circumstances where
there are no future performance requirements by the employees and non-employees, option, warrant and award grants are immediately vested
and the total stock-based compensation charge is recorded in the period of the measurement date.
Segment
Reporting
ASC
Topic 280, “Segment Reporting,” requires use of the “management approach” model for segment reporting. The management
approach model is based on the way a company’s chief operating decision maker organizes segments within the Company for making
operating decisions assessing performance and allocating resources. Reportable segments are based on products and services, geography,
legal structure, management structure, or any other manner in which management disaggregates a company.
The
Company manages its business as a single operating segment in the PRC. Substantially all of its revenues are derived in the PRC. All
long-lived assets are located in PRC.
New
Accounting Pronouncements
In
June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected
credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and
supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial
assets measured at amortized cost. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2022. Early application will be permitted for all entities for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2018. The Company is currently evaluating the impact that the standard will have on its consolidated
financial statements.
In
March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848) (“ASU 2020-04”). ASU 2020-04 contains practical
expedients for reference rate reform related activities that impact debt, leases, derivatives and other contracts. The guidance in ASU
2020-04 is optional and may be elected over time as reference rate reform activities occur. The Company continues to evaluate the impact
of the guidance and may apply the elections as applicable as changes in the market occur.
3.
ADVANCES TO SUPPLIERS
The
Company had advances to suppliers of $271,130 and $155,686 as of June 30, 2021 and December 31, 2020, respectively. Advances
to suppliers primarily include prepayments for products expected to be delivered subsequent to balance sheet dates.
4.
INVENTORY
Inventory
consisted of the following at June 30,
2021 and December 31, 2020:
SCHEDULE OF INVENTORY
|
|
June 30, 2021
|
|
|
December 31, 2020
|
|
Finished goods – health supplements
|
|
$
|
135,066
|
|
|
$
|
45,535
|
|
5.
PREPAYMENT FOR ACQUISITION
On
May 25, 2021, the Company entered into an Equity Transfer Agreement with Chengdu Aixin Shangyan Hotel Management Co., Ltd (“Aixin
Shangyan Hotel”), and its two shareholders Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life) and
Yirong Shen (“Transferor”).
Pursuant to the agreement (the “Hotel Purchase Agreement”), Aixin Life agreed to purchase 100%
ownership of Aixin Shangyan Hotel from Mr. Lin and Ms. Shen. Eighty
percent of the equity of Aixin Shangyan Hotel
is owned by Mr. Lin, and the remaining balance is owned by Ms. Shen.
Under the terms of the Hotel Purchase Agreement, Aixin Life agreed to purchase all of the outstanding equity of Aixin Shangyan Hotel
for a purchase price of RMB 7,598,887,
or approximately $1.16
million (“Transfer Price”). The Transfer
Price will be reduced by an amount equal to any amounts paid or distributed by Aixin Shangyan Hotel to the Transferor after December
31, 2020 and will be increased by an amount equal to any amounts contributed to Aixin Shangyan Hotel by the Transferor after December
31, 2020.
On
June 2, 2021, Aixin HK, a wholly owned subsidiary of Aixin Life, entered into an Equity Transfer Agreement (the “Transfer
Agreement”) with Chengdu Aixintang Pharmacy Co., Ltd. and certain affiliated entities, each of which operates a pharmacy (“Aixintang
Pharmacies”) and its three shareholders, Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life), Ting Li and Xiao Ling Li (“Transferor”). Mr. Lin owns in excess of
95% of the outstanding equity the Aixintang Pharmacies. The remaining equity interest is owned by Ting Li and Xiao Ling Li.
Pursuant
to the Transfer Agreement, Aixin HK agreed to purchase all of the outstanding equity of Aixintang Pharmacies for an aggregate purchase
price of RMB 34,635,845, or approximately US$5.31 million (“Transfer Price”). The Transfer Price will be reduced by an amount
equal to any amounts paid or distributed by any of the Aixintang Pharmacies to the Transferor after December 31, 2020 and increased by
an amount contributed to any of the Aixintang Pharmacies by the Transferor after such date.
As
of June 30, 2021, these two acquisitions have not yet been completed, and the Company prepaid $4,504,418 for the acquisition price.
6.
LOAN TO THIRD PARTY
On
June 8, 2020, the Company entered into an unsecured loan agreement with a third party, pursuant to which the Company agreed to lend RMB
50,300,000, equivalent to $7,408,389, to the third party. This loan bears interest of RMB 74,000, equivalent to $10,718, per day, and
will mature on July 28, 2020. As of December 31, 2020, the Company has received the repayment of principal and interest in full amount,
and recorded interest income of $535,906 during the year ended December 31, 2020. Interest income related to such loan to third party
amounted to $231,506 during the three and six months ended June 30, 2020.
7.
PROPERTY AND EQUIPMENT, NET
Property
and equipment consisted of the following at June 30,
2021 and December 31, 2020:
SCHEDULE OF PROPERTY AND EQUIPMENT
|
|
June
30, 2021
|
|
|
December 31, 2020
|
|
Vehicles
|
|
$
|
291,662
|
|
|
$
|
288,604
|
|
Office furniture
|
|
|
48,976
|
|
|
|
48,464
|
|
Electronic equipment
|
|
|
15,010
|
|
|
|
14,852
|
|
Total
|
|
|
355,648
|
|
|
|
351,920
|
|
Less: Accumulated depreciation
|
|
|
(298,005
|
)
|
|
|
(284,103
|
)
|
Property and equipment, net
|
|
$
|
57,643
|
|
|
$
|
67,817
|
|
Depreciation
expense for the three months ended June 30, 2021 and 2020 was $3,645 and $12,209, respectively. Depreciation expense for the six months
ended June 30, 2021 and 2020 was $10,870 and $24,811, respectively.
8.
TAXES PAYABLE
Taxes
payable consisted of the following at June 30,
2021 and December 31, 2020:
SCHEDULE OF TAXES PAYABLE
|
|
June
30, 2021
|
|
|
December 31, 2020
|
|
Value-added
|
|
$
|
48,608
|
|
|
$
|
32,318
|
|
Income
|
|
|
173,394
|
|
|
|
235,300
|
|
City construction
|
|
|
3,564
|
|
|
|
2,422
|
|
Education
|
|
|
2,597
|
|
|
|
1,781
|
|
Other
|
|
|
11,178
|
|
|
|
11,674
|
|
Taxes payable
|
|
$
|
239,341
|
|
|
$
|
283,495
|
|
9.
ACCRUED LIABILITIES AND OTHER PAYABLES
Accrued
liabilities and other payables consisted of the following at June
30, 2021 and December 31, 2020:
SCHEDULE
OF ACCRUED LIABILITIES AND OTHER PAYABLES
|
|
June 30,
2021
|
|
|
December 31,
2020
|
|
Accrued employees’ social insurance
|
|
$
|
361,812
|
|
|
$
|
364,870
|
|
Accrued professional fees
|
|
|
49,753
|
|
|
|
16,927
|
|
Accrued payroll and commission
|
|
|
118,427
|
|
|
|
105,844
|
|
Other payables
|
|
|
11,950
|
|
|
|
26,598
|
|
Total
|
|
$
|
541,942
|
|
|
$
|
514,239
|
|
10.
LEASE
On
September 12, 2018, the Company entered into a contract to sell its rights to a portion of a building with a buyer (the “Buyer”),
at which time the Buyer paid RMB 100,000 ($14,898) to a shareholder of the Company as a down payment. The contract stipulated the remaining
RMB 8,900,000 ($1,325,964) should be paid by the Buyer on or before September 30, 2018 and before the Company would be required to go
to the relevant authority to effectuate the transfer of its property rights. The Buyer failed to make the payment on or prior to September
30, 2018, a default under the contract which gave the Company the right to terminate the contract. In October 2018, the Buyer delivered
to the shareholder an additional RMB 7 million ($1.0 million). On March 25, 2019, the parties entered into a supplemental agreement which
provided that the Company would transfer the property rights to Buyer if it agreed the Company would get the benefit of the RMB 7,000,000
($1,042,893) and otherwise pay the remaining balance of RMB 1,200,000 ($178,782) on or prior to March 31, 2019. The RMB 1,200,000 ($178,782)
was paid directly to the shareholder on a timely basis and the Company was given the benefit of the RMB 8,900,000 ($1,325,964) delivered
to the Shareholder. The cost and accumulated depreciation of the building was $1,739,228 and $364,834,
respectively. The Company recorded a loss on sale of $32,945 during the nine months ended September 30, 2019. $1,340,862 of the proceeds
from the sale was collected by the principal shareholder which was offset against amounts due to the shareholder.
Concurrent
with the completion of this sale, the Company entered into an agreement to lease a portion of the building back from the Buyer over a
lease term of 2 years. The Company accounted for this lease as an operating lease right-of-use asset and a corresponding operating lease
liability in accordance with the Lease Standard. As a result, $207,049 (RMB 1,389,731) was recorded as operating lease right-of-use asset
and lease liability on March 31, 2019 when the lease commenced based on a 4.75% discount factor. The lease agreement expired on March
31, 2021. Commencing in April, 2021, the Company continues to lease the office on a monthly basis.
The
Company also has operating leases for other sales locations under various operating lease arrangements. The leases have remaining lease
terms of approximately 1 month to 5 years.
Balance
sheet information related to the Company’s leases is presented below:
SCHEDULE
OF OPERATING LEASE LIABILITIES
|
|
June 30,
2021
|
|
|
December 31,
2020
|
|
Operating Leases
|
|
|
|
|
|
|
|
|
Operating lease right-of-use assets
|
|
$
|
84,117
|
|
|
$
|
100,029
|
|
|
|
|
|
|
|
|
|
|
Operating lease liabilities - current
|
|
$
|
37,551
|
|
|
$
|
70,780
|
|
Operating lease liability – non-current
|
|
|
46,566
|
|
|
|
29,250
|
|
Total operating lease liabilities
|
|
$
|
84,117
|
|
|
$
|
100,030
|
|
The
following provides details of the Company’s lease expenses:
SCHEDULE
OF OPERATING LEASE EXPENSES
|
|
Six Months Ended June 30,
|
|
|
|
2021
|
|
|
2020
|
|
Operating lease expenses
|
|
$
|
56,253
|
|
|
$
|
52,744
|
|
|
|
Three Months Ended June 30,
|
|
|
|
2021
|
|
|
2020
|
|
Operating lease expenses
|
|
$
|
14,953
|
|
|
$
|
13,203
|
|
Other
information related to leases is presented below:
SCHEDULE
OF OTHER INFORMATION RELATED LEASES
|
|
Six Months Ended June 30,
|
|
|
|
2021
|
|
|
2020
|
|
Cash Paid For Amounts Included In Measurement of Liabilities:
|
|
|
|
|
|
|
|
|
Operating cash flows from operating leases
|
|
$
|
56,253
|
|
|
|
52,744
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Remaining Lease Term:
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
2.66 years
|
|
|
|
1.65 years
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Discount Rate:
|
|
|
|
|
|
|
|
|
Operating leases
|
|
|
4.75
|
%
|
|
|
4.75
|
%
|
Maturities
of lease liabilities were as follows:
SCHEDULE
OF MATURITIES OF LEASE LIABILITIES
For the year ending December 31:
|
|
|
|
2021 (excluding the six months ended June 30, 2021)
|
|
$
|
40,440
|
|
2022
|
|
|
15,729
|
|
2023
|
|
|
21,273
|
|
2024
|
|
|
6,356
|
|
2025
|
|
|
3,903
|
|
Thereafter
|
|
|
1,626
|
|
Total lease payments
|
|
|
89,327
|
|
Less: imputed interest
|
|
|
(5,210
|
)
|
Total lease liabilities
|
|
|
84,117
|
|
Less: current portion
|
|
|
(37,551
|
)
|
Lease liabilities – non-current portion
|
|
$
|
46,566
|
|
11.
RELATED PARTY TRANSACTIONS
Advance
to related parties
SCHEDULE
OF RELATED PARTY TRANSACTIONS
Advance
to related parties consisted of the following as of the periods indicated:
|
|
June 30, 2021
|
|
|
December 31, 2020
|
|
Qionglai Weide Pharmacy
|
|
$
|
-
|
|
|
$
|
10,421
|
|
Quanzhong Lin
|
|
|
199,843
|
|
|
|
-
|
|
Chengdu Xindu Cundetang Pharmacy Co., Ltd.
|
|
|
-
|
|
|
|
5,318
|
|
Total
|
|
$
|
199,843
|
|
|
$
|
15,739
|
|
Advance to related parties
|
|
$
|
199,843
|
|
|
$
|
15,739
|
|
Qionglai
Weide Pharmacy and Chengdu Xindu Cundetang Pharmacy Co., Ltd. are
controlled by Mr. Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life). The advances were for working capital
purpose, payable on demand, and bear no interest.
Advance
from related parties
Advance
from related parties consisted of the following as of the periods indicated:
|
|
June 30, 2021
|
|
|
December 31, 2020
|
|
Quanzhong Lin
|
|
$
|
-
|
|
|
$
|
258,862
|
|
Chengdu Aixin E-Commerce Company Ltd.
|
|
|
3,274
|
|
|
|
3,240
|
|
Chengdu Beibang Pharmacy
|
|
|
-
|
|
|
|
2,748
|
|
Total
|
|
$
|
3,274
|
|
|
$
|
264,850
|
|
Advance from related parties
|
|
$
|
3,274
|
|
|
$
|
264,850
|
|
Chengdu
Aixin E-Commerce Company Ltd. and Chengdu Beibang Pharmacy
are controlled by Mr. Quanzhong Lin (the Chairman, President and major shareholder of Aixin Life). These advances were for working
capital purpose, payable on demand, and bear no interest.
Office
lease from a Major Shareholder
In
May 2014, the Company entered a lease with its major shareholder for office use; the lease term was three years until May 2017 with an
option to renew. The monthly rent was RMB 5,000 ($774), the Company was required to prepay each year’s annual rent at 15th of May
of each year. The Company renewed the lease until May 28, 2023 with monthly rents of RMB 5,000 ($774), payable quarterly. The future
annual minimum lease payment at June 30, 2021 is $9,293 and $8,518 for each of the year ended June 30, 2022 and 2023, respectively.
12.
INCOME TAXES
The
Company was incorporated in the United States of America (“USA”) and has operations in one tax jurisdiction, i.e. the PRC.
The Company generated substantially all of its sales from its operations in the PRC for the three
and six months ended June 30, 2021 and 2020, and recorded an income tax provision for each
of such periods.
China
has a tax rate of 25% for all enterprises (including foreign-invested enterprises).
Uncertain
Tax Positions
Interest
associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative
expenses in the statements of operations. For the three and six months ended June 30, 2021 and 2020, the Company had no unrecognized
tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.
13.
STOCKHOLDERS’ EQUITY
On
August 17, 2020, by unanimous written consent in lieu of a meeting, the Board adopted resolutions authorizing a one (1)-for-four (4)
reverse stock split and on August 19, 2020 filed Articles of Amendment to effect the reverse stock split with the Secretary of State
of the State of Colorado. The reverse stock split becomes effective on October 27, 2020. According to the Articles of Amendment, the
Company is authorized to issue 20,000,000 shares of blank check preferred stock at $0.001 par value and to reduce the number of authorized
common stock to 500,000,000 shares at $.00001 par value per share from 950,000,000 shares. All share and earnings per share information
has been retroactively adjusted to reflect the reverse stock split.
As
of June 30, 2021 and December 31, 2020, the Company had 49,999,891 common shares issued and outstanding.
In
June 2020, 35,049,685
shares owned by Quanzhong Lin (the Chairman,
President and major shareholder of Aixin Life) were cancelled.
Stock
Awards Issued for Services
On
October 22, 2019, the Company granted and issued 37,500 shares to its employees and contractors under its 2019 Equity Incentive Plan.
The stock awards were valued at $337,500 based on the post-split closing price of $9 on the grant date.
On
October 24, 2019, the Company granted and issued 550,000
shares to its employees and contractors under
its 2019 Equity Incentive Plan. The stock awards were valued at $1,520,200
based on the post-split closing price of $2.764
on the grant date.
The
stock awards will vest over five (5) years from the grant date, and the grantee will forfeit a portion of the shares granted (“Shares
Granted”) if the grantee is no longer employed by or contracted with the Company. Specifically, the grantee will forfeit 80% of
Shares Granted if no longer employed by or contracted with the Company on the date that is one year from the grant date, forfeit 60%
of Shares Granted if no longer employed by or contracted with the Company on the date that is two years from the grant date, forfeit
40% of Shares Granted if no longer employed by or contracted with the Company on the date that is three years from the grant date, and
forfeit 20% of Shares Granted if no longer employed by or contracted with the Company on the date that is four years from the grant date.
Effective on the 5th year from the grant date, none of the shares will be subject to forfeiture.
For
the three months ended June 30, 2021 and 2020, stock-based compensation expenses were $92,885. For the six months ended June 30, 2021
and 2020, stock-based compensation expenses were $185,770. As of June 30, 2021, unrecognized compensation expenses related to these stock
awards are $1,229,977. These expenses are expected to be recognized over 4 years.
14.
STATUTORY RESERVES
Pursuant
to the PRC corporate law, the Company is now only required to maintain one statutory reserve by appropriating from its after-tax profit
before declaration or payment of dividends. The statutory reserve represents restricted retained earnings.
Surplus
reserve fund
The
Company is now required to transfer 10% of its net income, as determined under PRC accounting rules and regulations, to a statutory surplus
reserve fund until such reserve balance reaches 50% of the Company’s registered capital. During the three and six months ended
June 30, 2021 and 2020, the Company did not make any contribution to statutory reserve fund.
The
surplus reserve fund is non-distributable other than during liquidation and can be used to fund previous years’ losses, if any,
and may be utilized for business expansion or converted into share capital by issuing new shares to existing shareholders in proportion
to their shareholding or by increasing the par value of the shares currently held by them, provided that the remaining reserve balance
after such issue is not less than 25% of the registered capital.
Common
welfare fund
Common
welfare fund is a voluntary fund to which the Company can elect to transfer 5% to 10% of its net income, as determined under PRC accounting
rules and regulations. The Company did not make any contribution to this fund during the three and six months ended June 30, 2021 and
2020.
This
fund can only be utilized on capital items for the collective benefit of the Company’s employees, such as construction of dormitories,
cafeteria facilities, and other staff welfare facilities. This fund is non-distributable other than upon liquidation.
15.
OPERATING CONTINGENCIES
The
Company’s operations in the PRC are subject to specific considerations and significant risks not typically associated with companies
in North America and Western Europe. These include risks associated with, among others, the political, economic and legal environments
and foreign currency exchange. The Company’s results may be adversely affected by changes in governmental policies with respect
to laws and regulations, anti-inflationary measures, currency conversion and remittance abroad, and rates and methods of taxation, among
other things.
The
Company’s sales, purchases and expenses are denominated in RMB and all of the Company’s assets and liabilities are also denominated
in RMB. The RMB is not freely convertible into foreign currencies under the current law. In China, foreign exchange transactions are
required by law to be transacted only by authorized financial institutions. Remittances in currencies other than RMB may require certain
supporting documentation to affect the remittance.
The
Company is, from time to time, involved in litigation incidental to the conduct of its business regarding merchandise sold, employment
matters, and litigation regarding intellectual property rights.
The
Company believes that current pending litigation will not have a material adverse effect on its consolidated financial position, results
of operations or cash flows.
16.
SUBSEQUENT EVENT
In July and August, 2021, the Company completed
the required governmental procedures and obtained the documents necessary to consider the acquisition of Aixin Shangyan Hotel and certain
of the affiliates of Aixintang Pharmacies completed (see Note 5).
Management
has evaluated subsequent events through the date which the consolidated financial statements were available to be issued. All subsequent
events requiring recognition as of June 30, 2021 have been incorporated into these consolidated financial statements and there are no
subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”